Evidence map›Paper›PMID 34478196›Full record

ArticleZoo biology2022

Immunocontraception of male and female giraffes using the GnRH vaccine Improvac®.

Franz Schwarzenberger, Pia Krawinkel, Sophia-Maria Jeserschek, Nicole Schauerte, Christina Geiger, Folko Balfanz, Tobias Knauf-Witzens, Florian Sicks, Eva Martinez Nevado, Gwendoline Anfray and 4 more

Open access · hybridAbstract read
In one paragraph

Article in Zoo biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 11 institutions in 6 countries.

Franz SchwarzenbergerDepartment of Biomedical Sciences, Physiology-Endocrinology, University of Veterinary Medicine, Vienna, Austria.
Pia KrawinkelZOOM Erlebniswelt, Gelsenkirchen, Germany.
Sophia-Maria JeserschekDepartment of Biomedical Sciences, Physiology-Endocrinology, University of Veterinary Medicine, Vienna, Austria.
Nicole SchauerteZoo Frankfurt, Frankfurt am Main, Germany.
Christina GeigerZoo Frankfurt, Frankfurt am Main, Germany.
Folko BalfanzTiergarten Schönbrunn, Vienna, Austria.
Tobias Knauf-WitzensWilhelma - der zoologisch-botanische Garten, Stuttgart, Germany.
Florian SicksTierpark Berlin-Friedrichsfelde, Berlin, Germany.
Eva Martinez NevadoZoo-Aquarium de Madrid, Madrid, Spain.
Gwendoline AnfrayZoo de Lyon, Lyon, France.
Anna HeinZoo Karlsruhe, Karlsruhe, Germany.
Christine Kaandorp-HuberGaiaZoo, Kerkrade, The Netherlands.
Sandra MarcordesAG Zoologischer Garten Köln, Cologne, Germany.
Betina VenshøjZoo Odense, Odense, Denmark.
Frankfurt Zoological Society · DEUniversity of Veterinary Medicine Vienna · ATAssociation of Zoos and Aquariums · USBerlin Zoological Garden · DECommunauté urbaine de Lyon · FREvangelische Kliniken Gelsenkirchen · DEKarlsruhe Institute of Technology · DEKema International (Netherlands) · NLKlinikum im Friedrichshain · DEOdense Municipality · DKUniversity of Cologne · DE

Funding

VetmedUni Vienna and the zoological institutions
6 · The paper itself

Abstract

The aim of this study was to develop protocols for contraception in both sexes of giraffes (Giraffa camelopardalis) by using the GnRH vaccine Improvac®. We evaluated the success of immunization by analyzing fecal reproductive hormone metabolites in female (n = 20) and male (n = 9) giraffes. Endocrine analysis provided the basis for the successful immunization protocol, as well as for assessing long-term effects. Reliable reduction of fecal steroid metabolites to baseline levels in female giraffes was achieved with three, and in males with four or five injections at 4-week intervals. Effective booster injections were administered at 2-month intervals in the first year of treatment and at three to 4-month intervals in the following years. In addition to endocrine analysis, we determined vaccination efficacy in bulls by assessing testicular atrophy. Long-term (>2 years) use in females was often accompanied by prolonged periods of persistent corpus luteum activity, although normal cycles were not observed. Problems might occur with reversibility, because in a few males and females, even after more than 2 years since treatment had been stopped, fecal hormone metabolites have not returned to pretreatment levels. The results are somewhat ambiguous, as reproduction can be suppressed by use of Improvac®, but the question of reversibility remains unsolved.

Indexed as

Contraception, ImmunologicGiraffesVaccinesAnimalsAnimals, ZooFemaleGonadotropin-Releasing HormoneMaleGonadotropin-Releasing HormoneVaccinescontraception efficacy and reversibilityendocrine monitoringreproduction management

Identifiers

PMID34478196
PMCPMC9292419
OpenAlexW3196833269

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.